ORPHA:584
Mucopolysaccharidosis type 7
Also known as: Beta-glucuronidase deficiency · MPS7 · MPSVII · Mucopolysaccharidosis type VII · Sly disease
Publications
7,749
Trials
7
Interventional, condition-specific
Researchers
1,168
Distinct authors in sample
Gene link
GUSB
Definitive
Readiness
6/6
Stages with a signal
Clinical definition (Orphanet)
A rare, genetic lysosomal storage disease characterized by accumulation of glycosaminoglycans in connective tissue which results in multisystem involvement with severity ranging from mild to severe. The most consistent features include musculoskeletal involvement (particularly dysostosis multiplex, joint restriction, thorax abnormalities, and short stature), limited vocabulary, , coarse facies with a short neck, pulmonary involvement (predominantly decreased pulmonary function), corneal clouding, and cardiac valve disease.
How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0009662
- MeSH:D016538
- OMIM:253220
- UMLS:C0085132
- NCIT:C84903
Additional Mondo synonyms (6)
Mucopolysaccharidosis Type VII · Sly syndrome · beta-glucuronidase deficiency · mucopolysaccharidosis type 7 · mucopolysaccharidosis type VII · mucopolysaccharidosis, mps-VII
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
6/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedPresent
Definitive — GUSB
- LiteraturePresent
7,749 matched papers (4,818 in last 10 years) Source
- Phenotype characterisedPresent
91 HPO annotations (e.g. Inguinal hernia; Coarse facial features; Short neck) Source
- Animal modelPresent
10 genotype models (Mus musculus) Source
- Orphan designationPartial
1 FDA designation (none yet with FDA orphan-indication approval) — e.g. vestronidase alfa-vjbk Source
- Interventional trialPresent
7 matched on ClinicalTrials.gov
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Yes — we know a specific gene responsible (GUSB).
GenCC classification: Definitive.
Phenotypes (Monarch / HPO)
91
Associated phenotypes · MONDO:0009662
- Inguinal hernia
- Coarse facial features
- Short neck
- Lymphedema
- Intellectual disability
Showing 5 of 91 — open Monarch for the full list.
Animal models (Monarch / Alliance)
10
Model associations linked to this Mondo ID
- Hexatm1Rlp/Hexatm1Rlp Hexbtm1Rlp/Hexbtm1Rlp [background:] involves: 129S4/SvJae * C57BL/6·MGI:2177551·Mus musculus
- Gusbtm4Sly/Gusbtm4Sly [background:] involves: 129X1/SvJ * C57BL/6·MGI:2661058·Mus musculus
- Gusbmps-2J/Gusbmps-2J [background:] C3H/HeOuJ-Gusbmps-2J/BrkJ·MGI:2677921·Mus musculus
- Gusbmps/Gusbmps [background:] B6.C-H2-Kbm1/ByBir-Gusbmps/J·MGI:3758717·Mus musculus
- Gusbtm2Sly/Gusbtm2Sly [background:] involves: 129X1/SvJ * C57BL/6J·MGI:2451065·Mus musculus
- Gusbmps-3J/Gusbmps-3J [background:] C57BL/6J-Gusbmps-3J/J·MGI:3802703·Mus musculus
- Gusbmps/Gusbmps [background:] B6.Cg-Gusbmps/BrkJ·MGI:3784505·Mus musculus
- Gusbtm3Sly/Gusbtm3Sly [background:] involves: 129X1/SvJ * C57BL/6J·MGI:2451066·Mus musculus
- Gusbtm1Sly/Gusbtm1Sly [background:] involves: 129X1/SvJ * C57BL/6J·MGI:2451063·Mus musculus
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
1
Designation · no FDA orphan-indication approval yet
- FDA vestronidase alfa-vjbk (Mepsevii)Mucopolysaccharidosis VII · 2012-02-16
Sources: FDA OOPD · EMA orphan designations
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
7,749
7,749 papers — among the better-studied rare conditions, though still a fraction of common-disease literature (breast cancer: over 700,000). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
7,749 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
4,818 in the last 10 years · low confidence
Phrase hits: 975 · MeSH hits: 0
Who's working on it?
1,168
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Giugliani R8 papers · 2026
Hospital de Clínicas de Porto Alegre (HCPA), Serviço de Genética Médica, Porto Alegre, RS, Brazil.
Papers in Europe PMC - 02Casal ML7 papers · 2024
Department of Clinical Sciences and Advanced Medicine, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Papers in Europe PMC - 03Harmatz P6 papers · 2025
Fetal Treatment Center, University of California, San Francisco, CA, USA.
Papers in Europe PMC - 04Sands MS6 papers · 2017
2 Department of Internal Medicine, Washington University School of Medicine , St. Louis, Missouri.
Papers in Europe PMC - 05Sly WS6 papers · 2020
Saint Louis University School of Medicine, St. Louis, MO, United States. Electronic address: slyws@slu.edu.
Papers in Europe PMC - 06Smith LJ6 papers · 2024
Department of Orthopaedic Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Papers in Europe PMC - 07Kosuga M5 papers · 2025
Division of Medical Genetics, National Center for Child Health and Development, , Setagaya, Japan.
Papers in Europe PMC - 08Okuyama T5 papers · 2026
Department of Clinical Genomics, Saitama Medical University, Saitama, Japan.
Papers in Europe PMC - 09Datta R4 papers · 2025
Department of Biological Sciences, Indian Institute of Science Education and Research (IISER) Kolkata, Mohanpur, West Bengal, India. Electronic address: rupakdatta@iiserkol.ac.in.
Papers in Europe PMC - 10Lau YK4 papers · 2024
Department of Orthopaedic Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
7
interventional trials for this specific condition
7 interventional trials matched this specific condition name; none in our sample are currently recruiting. 101 trials are registered for mucopolysaccharidosis, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 11 September 2026 · last trial check 28 July 2026
7 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 90.9th percentile).
low confidence · 90.9th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
7 interventional trials matched after quoted-phrase search and title/condition post-filter.
No currently recruiting studies in the matched set. Open the same search on ClinicalTrials.gov.
Broader category: mucopolysaccharidosis
101
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT05594992·ENROLLING BY INVITATION·An Extension Study of JR-141 to Evaluate the Long-term Safety and Efficacy in MPS II (Hunter Syndrome) Subjects
Not reviewed·Conditions: Mucopolysaccharidosis II·Matched via name phrase
- NCT05208281·RECRUITING·A Multi-cohort Study of Safety, Efficacy, PK and PD of GNR-055 in Patients With Mucopolysaccharidosis Type II
Not reviewed·Conditions: Mucopolysaccharidosis Type II · Metabolic Diseases·Matched via name phrase
- NCT02716246·RECRUITING·Phase I/II/III Gene Transfer Clinical Trial of scAAV9.U1a.hSGSH
Not reviewed·Conditions: MPS IIIA · Sanfilippo Syndrome · Sanfilippo A · Mucopolysaccharidosis III·Matched via name phrase
- NCT05371613·RECRUITING·A Study to Determine the Efficacy and Safety of Tividenofusp Alfa (DNL310) vs Idursulfase in Pediatric and Young Adult Participants With Neuronopathic (nMPS II) or Non-Neuronopathic Mucopolysaccharidosis Type II (nnMPS II)
Not reviewed·Conditions: Mucopolysaccharidosis II·Matched via name phrase
- NCT07136896·NOT YET RECRUITING·Nutritional Assessment in Patient of Mucopolysaccharide "
Not reviewed·Conditions: Mucopolysaccharidosis (MPS) · Malnutrition (Calorie) · Undernutrition·Matched via name phrase
- NCT06075537·ENROLLING BY INVITATION·An Extension Study of the Long-Term Safety, Tolerability, and Efficacy of Tividenofusp Alfa (DNL310) in Participants With Mucopolysaccharidosis Type II (MPS II) From Study DNLI-E-0002 or Study DNLI-E-0007
Not reviewed·Conditions: Mucopolysaccharidosis II·Matched via name phrase
- NCT06519552·RECRUITING·A Clinical Study Evaluating the Safety, Tolerability, and Initial Efficacy of JWK008 in Patients With Mucopolysaccharidosis Type I
Not reviewed·Conditions: Mucopolysaccharidosis Type I·Matched via name phrase
- NCT06488924·RECRUITING·An Open-label Phase I/II Study of JR-446 in Mucopolysaccharidosis Type IIIB
Not reviewed·Conditions: Mucopolysaccharidosis III-B·Matched via name phrase
- NCT04360265·ENROLLING BY INVITATION·Follow-up Study of AAV-Mediated Gene Transfer (UX111; Previously Known as ABO-102) for MPS Type IIIA
Not reviewed·Conditions: Mucopolysaccharidosis IIIA · MPS IIIA · Sanfilippo Syndrome · Sanfilippo A·Matched via name phrase
- NCT02254863·RECRUITING·UCB Transplant of Inherited Metabolic Diseases With Administration of Intrathecal UCB Derived Oligodendrocyte-Like Cells
Not reviewed·Conditions: Adrenoleukodystrophy · Batten Disease · Mucopolysaccharidosis II · Leukodystrophy, Globoid Cell·Matched via name phrase
- NCT06333041·RECRUITING·Study of Cannabidiol in Sanfilippo Syndrome
Not reviewed·Conditions: Sanfilippo Syndrome · Mucopolysaccharidosis III·Matched via name phrase
- NCT07579910·NOT YET RECRUITING·Intracerebroventricular Tralesinidase Alfa in Children With Mucopolysaccharidosis Type IIIB
Not reviewed·Conditions: MPS IIIB·Matched via name phrase
- NCT05682144·RECRUITING·ISP-001: Sleeping Beauty Transposon-Engineered B Cells for MPS I
Not reviewed·Conditions: Mucopolysaccharidosis IH/S · Mucopolysaccharidosis IS·Matched via name phrase
- NCT07640984·NOT YET RECRUITING·A Phase I/II Trial of JR-446 in Mucopolysaccharidosis Type IIIB (MPS IIIB)
Not reviewed·Conditions: Mucopolysaccharidosis IIIB·Matched via name phrase
Observational and natural-history studies
4 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
Recruiting or not-yet-recruiting
- NCT03604835·RECRUITING·Mucopolysaccharidosis VII Disease Monitoring Program
Not reviewed·Conditions: Mucopolysaccharidosis VII · MPS VII · MPS 7 · Sly Syndrome·Matched via name phrase
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 6 · after dedupe 6 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 6 · dropped 0 · fetched 2026-07-29
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (6)
- isrctn·ISRCTN13397128·No longer recruiting·A study of potential treatment-responsive biomarkers and clinical outcomes in Hunter syndrome
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN16919215·No longer recruiting·Hydrotherapy in mucopolysaccharidosis II
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN10369994·No longer recruiting·A study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of MTL-CEBPA in children with mucopolysaccharidosis type IH
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN12458940·No longer recruiting·Gene therapy in children with mucopolysaccharidosis II (MPSII) consented below the age of 22 months
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN19853672·No longer recruiting·Intra-cerebral gene therapy for Sanfilippo type B syndrome
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN22324060·No longer recruiting·Efficacy and safety of enzyme replacement therapy for Mucopolysaccharidosis type I with 100 IU/Kg recombinant human a-L-iduronidase (Aldurazyme™)
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Mucopolysaccharidosis type 7 — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
("Mucopolysaccharidosis type 7" OR "Beta-glucuronidase deficiency" OR "MPSVII" OR "Mucopolysaccharidosis type VII" OR "Sly disease" OR "Sly syndrome" OR "mucopolysaccharidosis, mps-VII") OR ("GUSB" OR "GUSB syndrome" OR "GUSB-related")ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Mucopolysaccharidosis type 7" OR "Beta-glucuronidase deficiency" OR "MPSVII" OR "Mucopolysaccharidosis type VII" OR "Sly disease" OR "Sly syndrome" OR "mucopolysaccharidosis, mps-VII"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 7 interventional · 4 observational · 2 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"mucopolysaccharidosis"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Synonyms dropped by stoplist: MPS7
Confidence reasoning
- Preferred label is multi-word and distinctive
- 1 synonym(s) dropped by stoplist (may under-count)
- No label/synonym collisions with other diseases in this corpus
- Publication count (7749) is implausibly high for prevalence class "<1 / 1 000 000" — treat as possible over-matching, not a measure of research intensity
Ingested 2026-07-26T14:27:28.025Z
